

Table 1 Preoperative clinical data of patients with resectable pancreatic ductal adenocarcinoma who underwent surgery.

Characteristics	UFS group (n = 38)	GS group (n = 39)	P
Age (years)	67 (46–82)	65 (43–80)	0.359
Gender (male/female)	27/11	23/16	0.267
Location (head/body-tail)	26/12	23/16	0.389
Tumor size (mm)	25.4 (10–66)	23.1 (10.2–42)*	0.273
Biliary drainage (+)	21 (55%)	18 (46%)	0.424
CEA (ng/mL)	3.2 (1–40.3)	2.5 (1–40.3)*	0.783
CA19-9 (U/L)	260.5 (2–12000)	159 (2–2730)*	0.330
Dupan-2 (U/mL) †	81 (25–3000)	162 (25–4000)*	0.518
Span-1 (U/mL) ‡	41 (1–2170)	38 (1.3–270)*	0.315
Elastase-1 (ng/dL) ¶	334 (50–3528)	161 (25–3910)*	0.332

Data are expressed as median (range)

*Measurement before GS therapy

†Missing data (n = 3)

‡Missing data (n = 3)

¶Missing data (n = 7)

CA19-9 carbohydrate antigen 19-9, CEA carcinoembryonic antigen, Dupan-2 pancreatic cancer associated antigen, GS gemcitabine plus S-1, Span-1 S-pancreas-1, UFS upfront surgery.